BioPharmSignal logoBioPharmSignal

Biotech News

Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

Amneal Pharmaceuticals (AMRX)Amneal PharmaceuticalsEarnings

AMRX (AMRX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is amrx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

AMRXAmneal Pharmaceuticals2026-05-07 20:01 EST

Amneal Reports First Quarter 2026 Financial Results

AMRXAmneal Pharmaceuticals2026-02-27 11:00 EST

Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

CHRSCoherus BioSciences, Inc.2026-05-04 13:30 EST

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

View all latest news

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a global pharmaceutical company with generics, specialty products, and injectables. Its business is defined by scale, manufacturing, and portfolio breadth rather than early-stage biotech science.

Recent company news

AMRXAmneal Pharmaceuticals2026-07-17 12:00 EST

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

AMRXAmneal Pharmaceuticals2026-07-09 20:05 EST

Amneal to Report Second Quarter 2026 Results on July 30, 2026

AMRXAmneal Pharmaceuticals2026-07-08 20:30 EST

Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector

AMRXAmneal Pharmaceuticals2026-07-01 12:30 EST

Amneal’s New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program

AMRXAmneal Pharmaceuticals2026-06-29 07:00 EST

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

Stock data

Close
18.09 USD
Market cap
4.04B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States